Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 27 2019 - 05:51PM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
31st Annual Piper Jaffray Healthcare Conference on Tuesday December
3, 2019 at 2:00 pm, Eastern Time.
A live webcast of the presentation will be
available under the “For Investors” section of the Antares website,
www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused primarily on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
various stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s proprietary products include
XYOSTED® (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: successful development
including the timing and results of the clinical bridging and Phase
3 clinical trial of the drug device combination product for
Selatogrel with Idorsia Pharmaceuticals and FDA and global
regulatory approvals and future revenue from the same; market
acceptance, adequate reimbursement coverage and commercial success
of XYOSTED™ and future revenue from the same; market acceptance of
Teva’s generic epinephrine auto-injector product and future revenue
from the same; our expectations regarding whether the FDA will
pursue withdrawal of approval for AMAG Pharmaceuticals Inc.’s
Makena® subcutaneous auto injector following the recent FDA
advisory committee meeting and future prescriptions, market
acceptance and revenue from Makena® subcutaneous auto injector;
Teva’s ability to successfully commercialize VIBEX® Sumatriptan
Injection USP and the amount of revenue from the same; continued
growth of prescriptions and sales of OTREXUP®; the timing and
results of the Company’s or its partners’ research projects or
clinical trials of product candidates in development; actions
by the FDA or other regulatory agencies with respect to the
Company’s products or product candidates of its partners; continued
growth in product, development, licensing and royalty revenue;
achievement of the 2019 revised revenue guidance; the Company’s
ability to meet loan extension and interest only payment milestones
and the ability to repay the debt obligation to Hercules
Capital; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Mar 2023 to Mar 2024